Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 35 21 DAY versus NYLIA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 35 21 DAY versus NYLIA 1 35.
NORINYL 1+35 21-DAY vs NYLIA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady state achieved by day 10-14.
Norethindrone: 5-14 hours (mean ~8 hours); Ethinyl estradiol: 7-36 hours (mean ~14 hours). Clinically, steady-state is achieved within 5-7 days.
Renal (50-60% as metabolites, primarily glucuronide and sulfate conjugates) and fecal (30-40% as metabolites). Less than 1% excreted unchanged.
Renal: 40-60% (as metabolites, mainly ethinyl estradiol glucuronide and sulfate conjugates and norethindrone metabolites). Biliary/fecal: 30-50% (as conjugates and metabolites).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive